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Current strategies to amplify helper-dependent adenovirus, based on excision of the packaging signal, do not routinely reduce helper adenovirus
contamination below 1%. Here, we have tested if reducing the efficiency of the packaging process of the helper adenovirus could impair its packaging
without affecting helper-dependent adenovirus production. Interestingly, insertion of attB/attP-ΦC31 sequences flanking the packaging signal
significantly lengthens adenovirus cycle up to 60 h without reducing virus viability or production yield. This delay occurs in the absence of ΦC31
recombinase indicating that other mechanisms different from excision of packaging signal must be involved. In addition, at 36 h post-coinfection
helper-dependent adenovirus are efficiently produced, while production levels of helper attB/attP-modified adenovirus are 100–1000 times lower
than controls. Therefore, these results suggest that attB/attP-mediated packaging impairment of the adenovirus genome is an attractive strategy to
significantly reduce helper adenovirus contamination in helper-dependent adenovirus preparations, which in turn would facilitate scaling-up
processes for clinical grade preparations.
© 2007 Elsevier Inc. All rights reserved.Keywords: Helper-dependent adenovirus; Recombinase FC31; Adenovirus packagingIntroduction
The introduction of genetic material in target cells requires
the use of vectors that package and protect it from the intra- and
extracellular degradation, as well as to guide it to the expres-
sion site. In this regard, adenovirus (Ad) vectors are widely
used in gene therapy clinical trials (http://www.wiley.co.uk/
genmed/clinical for more information). To date, most adeno-
viruses used in preclinical and clinical assays have been deleted
in the E1 region or E1/E2 or E1/E4 regions (Amalfitano et al.,
1998). However, because adenovirus vectors are highly
immunogenic, helper-dependent (HD) adenoviruses, that lack⁎ Corresponding author. Center of Animal Biotechnology and Gene Therapy
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doi:10.1016/j.virol.2007.05.014all coding regions from wild-type adenovirus, have been
recently developed (for a recent review, see Alba et al., 2005).
In spite of their many advantages, HD Ad use in clinical trials
is not yet suitable due to low production yields, and the
presence of contaminating helper adenovirus generated during
their production (Ng and Graham, 2005), especially when high
doses must be administered.
The only viral DNA sequences remaining in the HD Ad
vector genome (less than 500 base pairs) are those required in cis
for genome packaging and replication. These sequences are the
packaging signal (Ψ) and the inverted terminal repeats (ITRs),
the sequences defining the ends of the viral genome (Horwitz,
1990). Thus, generation of HD Ad requires addition of proteins
in trans (Mitani et al., 1995; Parks et al., 1996). This is achieved
through the use of E1-deleted helper vectors. However, viral
proteins synthesized in trans allow for replication of both helper
and HD Ad genomes. Therefore, it is imperative to reduce or
Fig. 1. Adenovirus constructs Ad5/attP, Ad5/FC31.1 and Ad5/FC31.2 con-
taining the packaging signal flanked by different combinations of attB/attP
sequences and a reporter expression cassette.
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develop systems for selective and specific purification of HD
Ad. The most common strategy is to flank the Ψ of the helper
virus with loxP sequences (Chen et al., 1996; Ng et al., 1999).
The Ψ is eliminated through a amplification step in a Cre-
expressing 293 cell line, thus avoiding packaging of the helper
Ad genome without affecting the normal processing of the HD
Ad genome (whose Ψ sequence is not flanked by loxP sites).
However, there are still residual levels of helper virus (0.1% to
1% )(Mitani et al., 1995; Ng et al., 1999). This may be due to
escape from Cre-mediatedΨ excision due to limiting Cre-levels
(Ng et al., 2002), the acquisition of Cre-resistant mutations and/
or to reversibility of Cre reaction allowing reinsertion of the Ψ
into the helper vector genome. Efficient regulation of packaging
is therefore a key step in the production of high titer pure HD Ad
vectors.
To circumvent some of the drawbacks associated with the
Cre-mediated approach, we tested another recombinase: ΦC31.
In nature, ΦC31 is a unidirectional recombinase that carries out
the recombination between the phage (attP) site and the host
(attB) site, which are not identical (Thorpe et al., 2000). This
recombination is efficient in Escherichia coli and in mammalian
cells (Groth et al., 2000), with levels similar or better than Cre
and FLP recombinases (Andreas et al., 2002). Interestingly,
short fragments (less than 40 pb long) from attB and attP
sequences are still recognized by ΦC31 permitting efficient
excision (Groth et al., 2000).
Packaging of the adenoviral genome is a complex process
carried out via the interaction of specific viral proteins with the
Ψ (Erturk et al., 2003; Ostapchuk et al., 2005). Viral DNA is
inserted into the capsid in a sequential process to form a viral
particle. The Ψ can be located at either end of adenoviral
genome (Hearing et al., 1987), and mutations in Ψ can
significantly reduce the efficiency of the packaging process. In
addition, the distance between ITR and Ψ is crucial for
generating the packaging protein complex: increasing the
distance up to 270 bp does not notably affect packaging
efficiency, while inserting more than 270 bp, strongly affects the
packaging process (Hearing et al., 1987). Moreover, because the
sequences flanking Ψ are also involved in recombinase-
mediated excision processes during HD Ad amplification, a
better knowledge of how this region interacts with viral and
cellular proteins is needed.
Thus, taking into account that high levels of Cre expression
are toxic in mammalian cells as it induces chromosomal
aberrations and increases the number of sister chromatid
exchanges (Loonstra et al., 2001; Ng et al., 2002), together
with the lack of a direct effect of loxP sequences in the
packaging process, we analyzed whether the insertion of attB/
attP-ΦC31 sequences flanking the packaging signal could
significantly reduce packaging of helper adenovirus genomes,
either by promoting excision of Ψ and/or by disturbing the
interaction of Ψ with the packaging complex. Here, we show
that flanking Ψ with attB/attP-ΦC31 sequences impairs the
adenovirus packaging process which, in turn, significantly
lengthens the viral cell cycle, but without altering virus viability
or production yields.Results
Generation of attB/attP-modified adenovirus
A family of Ad5 genomes was generated by introducing
different combinations of attB/attP sequences flanking its
packaging signal. All constructs were incorporated into the
Ad5 genome through homologous recombination (see Fig. 1).
To facilitate tracing of virus amplification kinetics and titering,
we inserted a green fluorescent protein cassette (GFP) between
the Ψ signal and the attP sequence. Thus, we generated the
following vectors: Ad5/attP, with no attB site and just one attP
site to the right of Ψ (as control for ΦC31); Ad5/FC31.1 that
carries attB/attP sequences (attB sequence to the left of Ψ);
Ad5/FC31.2, also containing attB/attP sequences, where attB is
separated from Ψ by a 65-bp spacer sequence (to test the effect
of separating attB from Ψ), and Ad5/attB with no attP site and
just one attB site to the left ofΨ. We used a minimal attB region
of 53 nucleotides that allows full recombination with the attP
sequence in the presence of ΦC31 (Groth et al., 2000).
Production of attB/attP-modified adenovirus is affected at 36 h
and is not dependent on recombinase ΦC31
For initial production of viral preparations, HEK-293 and
HEK-293/FC31 cells (that express ΦC31) were infected with
Ad5/Bgal control, Ad5/attP, Ad5/FC31.1 or Ad5/FC31.2. Con-
sistently low levels of adenovirus vectors carrying both
attB/attP sequences were produced during the virus amplifica-
tion process. Thus, at a standard adenovirus production time
(36 h), the amount of infectious Ad5/FC31.1 and Ad5/FC31.2
produced (in IU/cell) in HEK-293/FC31 cells were strongly
reduced (N99.9%) compared to control Ad5/Bgal (Fig. 2A).
These results indicate abnormalities in the production process
that were clearly associated to the presence of both attB and
attP sequences flanking Ψ, regardless if attB was close to Ψ
or separated by a spacer. However, the presence of attP was not
sufficient to reduce production levels as Ad5/attP behaved as
the control vector. Interestingly, in HEK-293 cells the amount of
infectious Ad5/FC31.1 and Ad5/FC31.2 produced (in IU/cell)
Fig. 2. Viral production levels at 36 h post-infection of Ad5/Bgal, Ad5/attP,
Ad5/FC31.1 and Ad5/FC31.2 is not dependent on recombinase ΦC31. Newly
produced viruses were recovered from crude lysate and titered in HEK-293 cells.
IU were determined by end-point dilution assay by quantifying GFP-expressing
HEK-293 cells 30 h post-infection. Depending on the vector, data were obtained
from 4 to 10 independent experiments. (A) Viral production in HEK-293/FC31
cells. (B) Viral production in HEK-293 cells.
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Ad5/βgal (Fig 2B), indicating that other mechanisms not
dependent on the presence of the recombinase must be involved
in the low productions levels of attB/attP vectors. As expected,
in HEK-293 cells, Ad5/attP also behaved as control Ad5/Bgal.
In addition, the same results were observed also in N52.E6 cells
indicating that mechanisms are more general and not specific of
HEK-293 cells or derivatives (data not shown).
Packaging of attB/attP genomes into viral capside is impaired
at 36 h
We then analyzed whether packaging of genomes with Ψ
flanked by attB/attP sequences was affected. HEK-293 cells
were infected at an MOI of 5 with a control adenovirus (Ad5/
RFP), an attB/attP containing vector (Ad5/FC31.2) or both
together. In this experiment, the Ad5/RFP containing the RFP
reporter gene was used to facilitate analysis in coinfection
experiments. Moreover, since Ad5/FC31.1 and Ad5/FC31.2
amplify similarly only one (Ad5/FC31.2) was used. At 36 hpost-infection, viral genomes were recovered either from
infected cells or from virions and quantified by Southern blot
using a probe against adenovirus ITRs. As seen in Fig. 3A, viral
genomes of Ad5/RFP and Ad5/FC31.2 vectors were produced
at the same level when coinfected in the same cells (High
Molecular Weight DNA, lane Ad5/RFP+Ad5/FC31.2 and Fig.
3B). In fact, viral DNA production levels were similar either in
individual infections (controls) or coinfection. However,
analysis of packaged viral genomes in coinfected cells showed
that only 1–5% of Ad5/FC31.2 genomes were packaged into
virions compared to Ad5/RFP (Fig. 3B), suggesting that low
production levels at 36 h were likely due to impaired packaging
of genomes with their Ψ flanked by attB/attP sequences.
Viral cell cycle analysis of attB/attP-modified adenovirus
To test if attB/attP sequences were impairing the packaging
process by affecting packaging kinetics or packaging efficiency,
we analyzed production of attB-attP-modified vectors during the
first 72 h (2 standard viral cell cycles). HEK-293 cells were
incubated with control andmutant adenovirus at anMOI of 5 and
total virus production was determined every 4 h (Fig. 4). Similar
to our previous results, production of control Ad5 followed a
normal kinetic and reached a plateau after 36 h. Identical results
were observed for the Ad5/attP vector, which was subsequently
utilized as a control vector through the experiments. However,
production of Ad5/FC31.1 and Ad5/FC31.2 was slower and
reached a plateau about 56–60 h post-infection.
Once we determined that the viral amplification of both attB/
attP-modified adenovirus had a delay of about 20 h with respect
to control vectors, we compared whether virus production yield
was similar at the end of their viral cell cycle (Table 1).
Interestingly, virus yield from Ad5/FC31.2 at the end of its viral
cell cycle (60 h) was in the same range of that of the control
adenovirus, in contrast with significantly lower levels observed
at 36 h (Fig. 2). These data indicated that if we allow completion
of viral amplification, virus production efficiency and viability
of attB/attP-adenoviruses are greatly recovered.
Then, to test if the attB sequence was responsible for the
impairment of the packaging process, an adenovirus containing
only the attB (Ad5/attB) but not the attP site was generated.
HEK-293 cells were incubated with Ad5/attB at an MOI of 5
and total virus production was determined every 4 h (Fig. 4,
filled squares). Interestingly, viral cycle of Ad5/attB was similar
to Ad5/FC31.1 and Ad5/FC31.2 reaching a plateau about 56–
60 h post-infection, indicating that, when located at 5′ ofΨ, the
attB sequence must be responsible for the differential packa-
ging. In addition, as it happens for Ad5/FC31.1 and Ad5/
FC31.2, Ad5/attB production is very low at 36 h (data not
shown) while lengthening of the virus amplification process
allowed efficient Ad5/attB production (Table 1).
attB-modified vectors allow normal packaging of
helper-dependent adenovirus genomes
We finally tested if the delayed virus amplification cycle of
attB-modified vectors could be utilized for efficient production
Fig. 3. Analysis of adenovirus packaging. HEK-293 cells were infected with Ad5/RFP or Ad5/FC31.2 at an MOI of 5 IU/cell, or coinfected with both viruses (Ad5/
RFP and Ad5/FC31.2) at an MOI of 5 IU/cell per virus. (A) Total nuclear DNA (1 μg), encapsidated viral DNA (100 ng) and different amounts (6, 33, 100 and 300 ng)
of control viral DNA (dl309) were separated by gel electrophoresis and analyzed by Southern blot. DNA probe contained the first 194 nt of the adenoviral genome and
allows detection of Ad5/RFP (641-bp band) and Ad5/FC31.2 (2180-bp band) genomes. (B) Quantification of intracellular and packaged adenoviral genomes.
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minating helper vectors present in HD Ad preparations, we
transfected 293 cells using viral genomes from plasmids instead
of transducing from previously amplified viral vector stocks. As
HD Ad, Ad5/KCZ, a βgal-expressing vector, was used. CellsFig. 4. Viral life cycle of attB/attP-modified and control adenovirus. For each adenov
the IU value (100%) at the end of each viral life cycle.HEK-293 were cotransfected with both genomes (pAd5/
FC31.2, helper; and pKCZ, HD) at a molar ratio 1:1.
Interestingly, after analysis of whole virus sample, virus
quantification showed that only infectious HD Ad5/KCZ
particles were generated (average of 143.8 IU/106 cells), whileirus construct, Infectious Units (IU) were determined every 4 h and compared to
Fig. 5. Differential packaging of attB/attP-modified genomes versus defective
HD genomes. Plasmids pAd5/FC31.2 (attB-helper) and pKCZ (HD) were
cotransfected into HEK-293 cells at a molar ratio of 1:1. The experiment was
performed three times in triplicate and newly produced adenoviruses were
harvested 40 h and 60 h post-transduction and quantified by end-point dilution
assay.
Table 1
Viral production levels after viral cycle completion: Ad5/βgal (36 h), Ad5/RFP
(36 h), Ad5/attP (36 h), Ad5/FC31.1 (56 h) and Ad5/FC31.2 (56 h)
Adenovirus yield from purified preparations Ratio
IU/PP
Total IU Total PP
Ad5/Bgal 12.9×1010 3.1×1012 1:24
Ad5/RFP 7.1×1010 3.6×1011 1:5
Ad5/attP 16.0×1010 5.9×1012 1:37
Ad5/FC31.1 3.6×1010 1.1×1012 1:30
Ad5/FC31.2 2.6×1010 1.6×1012 1:62
Ad5/attB 7.1×1010 1.7×1012 1:24
Data obtained from one cesium chloride-purified viral preparation of twenty
15-cm plates. IU were determined by end-point dilution assay by quantifying
GFP-expressing HEK-293 cells, 30 h post-infection.
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Amplified viruses were also recovered 60 h post-transduction
(Fig. 5). As expected, at 60 h, infectious helper-dependent Ad5/
KCZ virus yield was significantly higher (790 IU /106 cells) than
at 36 h. These data demonstrated that attB-modified genomes
permit packaging and amplification of defective helper-
dependent Ad vectors.
Discussion
To date, different strategies have been developed to produce
HD Ad vectors, most of them by impairing packaging of the
helper adenovirus genome mainly by the use of recombinases
(Parks et al., 1996; Sakhuja et al., 2003; Umana et al., 2001).
More recently, packaging impairment has been coupled to
differential centrifugation by using helper and HD Ad genomes
of different size (Sakhuja et al., 2003; Sargent et al., 2004).
This system has permitted the reduction of helper contaminat-
ing levels down to 0.01–0.1%, which could be the first step to
allow their use in human clinical trials. However, the efficiency
of Cre and FLPe recombinases is limited due to their toxicity
and their reversibility (Loonstra et al., 2001). Similarly, to
reduce helper virus contamination in HD Ad preparations,
other strategies also target the packaging process by direct
mutation of Ψ either by deleting or mutating packaging
sequences or a combination of both (Alemany et al., 1997;
Kochanek et al., 1996; Soudais et al., 2001). However, none of
these strategies is able to routinely reduce helper-contamination
below 0.1–1%.
To further impair selective packaging of the helper virus
genome, we hypothesized that the recombinaseΦC31 and attB/
attP sequences could be more efficient because it mediates an
unidirectional excision, it is active in human cells (Thorpe et al.,
2000), and its excision efficiency is similar to Cre and FLPe
(Andreas et al., 2002). To study how the packaging process was
affected, we flanked the Ψ signal of Ad5 with different
combinations of attB/attP sequences from ΦC31 (Fig. 1). From
initial steps of virus amplification (36 h), we observed very low
yields in two out of three vector genomes (Ad5/FC31.1 and
Ad5/FC31.2) of about 0.5–1% of those observed for controls
(Fig. 2). Of note, the Ad5/attP vector behaved as the normalcontrol adenovirus suggesting that attB, inserted to the left ofΨ
(either alone or in combination with attP) must be a key factor
for low production yields. Surprisingly, these low yields were
observed not only in a ΦC31 expressing HEK-293 cell line
(Thyagarajan et al., 2000) but also in non-expressingΦC31 cell
lines (HEK-293 and N52.E6), indicating that mechanisms
involved were independent on the presence of the recombinase
and not restricted to a specific cell line.
Since Ψ was flanked by attB and attP sequences, we first
tested if the packaging process was affected. Comparison
between the replicated Ad and packaged Ad genomes revealed
that the attB/attP-modified genomes where equally produced
but differentially packaged (Fig. 3), suggesting that an abnormal
packaging process could likely be the main cause for low
production yields. In agreement with these results, we observed
that only attB/attP-modified vectors clearly lengthened their
viral cell cycle (from 36 to 56–60 h) (Fig. 4). However, pro-
duction yields of attB/attP-modified vectors were similar to
controls when allowed to complete their viral amplification,
indicating that only packaging kinetics, but not packaging
efficiency, was affected.
Interestingly, only Ad5/attB but not Ad5/attP has an im-
portant delay in the viral cell cycle (Fig 4) indicating that,
when located at 5′ of Ψ, the attB sequence is able to cause the
delay. Different hypotheses could explain differential amplifi-
cation of attB-containing vectors. One possibility is an impair-
ment of the packaging process due to the 53-bp attB sequence
that we have introduced between left-ITR and Ψ. It is known
that the distance between ITR and Ψ can be crucial for an
efficient packaging process. However, this seems unlikely
since at least 270 or more nucleotides are required to impair
packaging (Hearing et al., 1987). In addition, we have not seen
any difference between Ad5/FC31.1 and Ad5/FC31.2, which
only differ in a 65-bp long spacer between attB and Ψ.
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to DNA and therefore affect binding of the packaging complex
to Ψ, thus delaying the packaging process and thereof,
lengthening the viral cell cycle. Other possibilities may
involve an intracellular factor or a viral protein that may
bind the attB sequence, hence either impairing direct binding
of the packaging complex to Ψ or keeping the adenovirus
genome in an abnormal intracellular location away from the
packaging complex. Cloning attB in other regions of the
adenovirus genome may help to determine the mechanisms
involved.
Finally, plasmid pAd5/FC31.2 was cotransfected with a
plasmid containing a defective HD Ad genome (pKCZ)
carrying a βgal cassette (Fig. 5). Of note, at 36–40 h, only
infectious particles of HD Ad vector Ad5/KCZ were observed.
Not a single infectious particle of attB/attP-vector Ad5/FC31.2
could be detected at this time point. Therefore, this experiment
clearly shows that an attB/attP-containing genome is able to
provide viral proteins to allow correct packaging and produc-
tion of defective HD Ad vector. Surprisingly, the yield of the
attB/attP-containing genome also was significantly reduced at
60 h after infection in cotransfections with pKCZ. This is in
contrast to normal virus yield with the attB/attP-containing
virus in single infections (Table 1). This result may reflect a
competition for packaging between the wild type packaging
signal in the pKCZ genome and the attB-compromised
packaging signal in the attB/attP-containing genome. The
regulation of viral DNA packaging via competition for limiting
trans-acting packaging factors in coinfection experiments was
previously suggested based on similar results (Schmid and
Hearing, 1997).
In conclusion, we described the generation of adenoviruses
containing attB/attP-ΦC31 sequences flanking the Ψ signal.
These vectors have a delayed viral life cycle, likely caused by
the insertion of the attB-ΦC31 sequence to the left of Ψ, and
show low production yields at 36 h post-infection but normal
titers when infections were allowed to proceed for longer
periods of times. This is the first time that a protocol is described
for the selective regulation of Ad packaging that is not based on
recombinase-mediated excision of Ψ but rather on differential
packaging kinetics. This system is very efficient in selectively
avoiding the packaging of a specific adenovirus genome. For
this reason, these results may have profound implications in
helper-free HD Ad production, as we can selectively avoid
packaging of the helper virus, regardless of the expression of
specific recombinases. Large-scale production of HD Ad may
be facilitated by controlling the harvesting time of infected cells.
Indeed, further experiments like detailed analysis of the
different steps of the viral cell cycle, identification of cell
proteins interacting with attB and/or attP, studies of their
packaging process in different cell lines (including those
expressing recombinase ΦC31) and optimization and full
production of HD Ad using attB/attP-vectors as helpers may
help to characterize and understand the mechanisms involved in
the lengthening of the viral cell cycle of attB/attP-containing
adenovirus, as well as their potential to significantly reduce
helper contamination in HD Ad preparations.Material and methods
Construction of attB/attP containing plasmids
pBCPB+ was kindly provided by Dr. Michele Calos
(Stanford University, USA) (Groth et al., 2000), pKP1.4ΔCMV
by Dr. Eric Kremer and pTG-6600 by Dr. Olivier Danos. Other
plasmids used are pXL-TOPO (Invitrogen, La Jolla, CA, USA),
pGEMT-easy (Promega, Madison, WI, USA), peGFP-C1 (BD-
Clontech, San Jose CA, USA) and pDSRed2-Mito (BD
Biosciences). To delete the multicloning site of pTG-6600,
this plasmid was digested with EcoRI and MfeI creating 3
fragments of 5310, 616 and 183 base pairs (bp). Fragments
5310 and 616 bp were religated to generate pTG-6600-ΔCMV.
pBCPB+ was digested with SpeI to obtain the attP region
(221 bp from ΦC31 bacteriophage), that was cloned into
pTG-6600-ΔCMV digested with SpeI and NheI to generate
pTG-6600ΔCMVΨattP. pKS-RSV/GFP (donor of GFP cas-
sette) and pTG-6600ΔCMVΨattP were both digested with SalI
and SpeI to generate pTG-6600ΔCMVΨGFPattP (pRAF2.1).
Directed mutagenesis was performed in plasmid pTG-6600-
ΔCMVΨattP with primers MutDIRAgeI: 5′-CAC CGG TGT
ACA CAG GAA GTG ACA A-3′ and MutREVAgeI: 5′-CAC
CGG TGT ACA CAC CAA AAA CGT C-3′ to introduce an
AgeI site in the nucleotide 189 and generate pTG-6600ΔCMV
(AgeI)ΨattP. attB+ spacer sequence was cloned into a pGEMT-
easy vector to generate pGEMT-attB.2 by using primers attB.2-
DIR 5′-TTATAA AGG TAC CCA CCG GTC CGC GGT GCG
GGT GCC AGG GCG TGC CCT TGG GCT CCC CGG GCG
CGT ACT CCA CGC GGC CG CAT-3′ and attB.2-REV 5′-
TTA TAA ACA CCG GTC GCG GCC GCA TAA CTT
CGT ATA ATG TAT GCT ATA CGA AGT TAT GCG GCC
GCG TGG AGT ACG CGC-3′. pGEMT-attB.2 and pTG-
6600ΔCMV(AgeI)ΨGFPattPwere both digested with AgeI and
the 140-bp fragment (attB.2) cloned to generate pTG-6600-
ΔCMVattB.2ΨGFPattP (pRAF5.1). Then pRAF5.1 was
digested with NotI to delete the spacer and further religated to
generate pTG-6600ΔCMVattB.1ΨGFPattP (pRAF1.2). To
generate pTG-6600ΔCMVattB.2ΨGFP (pRAF4.1) attP
sequence was removed from pRAF5.1. To generate Ad5/RFP,
pDSRed2-Mito and pTG-6600 were digested with SnaBI and
EcoRI. A 5685-bp band from pTG-6600 and a 1149-bp band
from pDSRed2-Mito were isolated and ligated to generate
pTG-6600/RFP (Red Fluorescent Protein). The RFP gene carries
a mitochondrial targeting sequence.
Prior to homologous recombination (Chartier et al., 1996),
pKP1.4ΔCMV was digested with SwaI, while pRAF2.1,
pRAF5.1, pRAF1.2, pRAF4.1 and p6600/RFP were all
linearized with XmnI and transformed in BJ5183 bacteria to
generate the different control and attB/attP-modified adenovirus
genomes: pAd5/attP, pAd5/FC31.1, pAd5/FC31.2, pAd5/attB
and pKP/RFP. In order to discard any inadvertent secondary
mutation, we sequenced every recombinant adenovirus genome
from the left ITR to nucleotide 5788 of Ad5, which is the last
adenoviral nucleotide of the shuttle vectors involved in the
generation of the adenoviral genome by recombination. As
expected, we found no mutation/change/variation in any of the
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cing Service of the Universitat Autònoma de Barcelona, Spain.
Adenovirus generation, production and purification
All adenoviral vectors were produced at the Vector Produc-
tion Unit in the Center of Animal Biotechnology and Gene
Therapy at the Universitat Autònoma of Barcelona (Barcelona,
Spain). HEK-293 cells (Q-BIOgene, Montreal, Canada) were
grown in DMEM medium (#E15-810, PAA laboratories, Linz,
Austria) and 10% of fetal bovine serum (FBS) (PAA labo-
ratories, Linz, Austria) and transfected with Polyethylenimine
(PEI, 25 kDa, Aldrich, St. Louis,MO, USA) (2.25 μl PEI 10mM
per 1 μg of DNA), with different linear PacI-digested plasmids
containing adenoviral genomes. The initial transfection step was
allowed to proceed until viral foci were observed: 3 days for
pAd5/attP or 8–10 days for pAd5/FC31.1 and pAd5/FC31.2.
Virus stocks were sequentially amplified until twenty 15-cm
plates were reached, allowing 36 h per step for Ad5/Bgal and
Ad5/attP and 60 h per step for Ad5/FC31.1 and Ad5/FC31.2. In
all cases, the cell pellet was concentrated to a final volume of
40–45 ml, and three freeze/thaw rounds were performed to
liberate virus particles. Supernatant was centrifuged in two
consecutive CsCl2 gradients [(a) step gradient of 1.40 g/cm
3–
1.25 g/cm3; and (b) an isopycnic gradient of 1.35 g/cm3] to
purify viral particles and desalted using a Sephadex PD-10
desalting column (Amersham Biosciences, Uppsala, Sweden)
to remove CsCl2. Final purified viral stocks were titered by
determining their concentration (particles/ml) by optical
density at 260 nm (1 OD260 unit=1×10
12 particles/ml), and
their infectivity (infectious units/ml) was measured by end-
point dilution assay. Briefly, end-point dilution assays were
performed in triplicate by infecting 293 cells with serially
diluted vectors, and then counting the number of transgene
(GFP or βgal) expressing cells after 24 h (Zabner et al., 1999).
The particle to infectious unit ratio of adenovirus used in the
experiments had an average of 40:1.
Viral production assay
HEK-293 cells were infected with Ad5/Bgal, Ad5/attP, Ad5/
FC31.1 or Ad5/FC31.2 at 5 IU/cell in a 6-well plate. Samples
were washed 6 h later with fresh DMEMmedium and pellet and
supernatant harvested at 36 and 56 h p.i. Virus particles were
liberated and titer calculated at each time point by end-point
dilution assay.
Analysis of adenovirus packaging
HEK-293 cells were infected with Ad5/RFP or Ad5/FC31.2
in 5×15 cm plates at an MOI of 5 IU/cell. For coinfection
experiments, HEK-293 cells were coinfected with both viruses
(Ad5/RFP and Ad5/FC31.2) at an MOI of 5 IU/cell per virus.
Infected cells were harvested at 36 h post-infection. Most of the
cell suspension sample (94%) was used to prepare encapsidated
viral DNA following the protocol described by Gräble and
collaborators (Grable and Hearing, 1990). The rest of the sample(6%) was used to isolate total nuclear DNA by lysing the cells
with Nonidet P-40 (0.6%) and precipitating the nuclei. Total
nuclear DNA (1 μg) and encapsidated viral DNA (100 ng) were
digested with SpeI, separated by gel electrophoresis and
analyzed by Southern blot. In addition, we used different
amounts (6, 33, 100 and 300 ng) of control viral DNA (dl309)
(Jones and Shenk, 1979) digested with XbaI to quantify sample
DNA. As a probe for Southern blot analysis, a sequence
containing the first 194 nt of the adenoviral genome was labeled
with 32P by random primer method (Feinberg and Vogelstein,
1983). Viral genomes were analyzed using a PhosphorImager
(ABI Storm 680), ImageQuant software and quantified by
comparing with control viral DNA from dl309. Adenovirus
packaging efficiency was calculated as the number of copies of
attB-modified adenovirus (Ad5/FC31.2) divided by the number
of copies of control Ad (Ad/RFP) in coinfection experiments.
Determination of viral life cycle
HEK-293 cells were infected with control Ad5/Bgal, Ad5/
attP and Ad5/FC31.2 at 5 infectious units per cell (also at 1
and 0.2 infectious units per cell, data not shown), at 70 to 80%
confluency in a 24-well plate. Sampleswere recovered (pellet and
supernatant) every 4 h, up to 72 h. Three freeze/thaw rounds were
performed to liberate virus particles and number of IU/cell at each
time point calculated by end-point dilution assay. Viral life cycle
was defined as the process from virus entry into the cell to
formation of infective virus particles. End of viral life cycle was
defined as the time when the IU/cell number reached a plateau
(values do not increase or even decrease compared to values of
previous time points), after a period of maintained exponential
amplification of at least 12 h. To avoid the effects of a second
amplification cycle, once the end of a viral life cycle was defined
for a given vector, further time points were considered as plateau.
Cotransfection assay
HEK-293 cells in a 6-well plate were transfected with 3 μg of
defective HD adenoviral plasmid pKCZ and 3 μg of helper
plasmid pKP/FC31.2 in triplicate with PEI in serum-free media.
Four hours later, the media were replaced by media with 10%
FBS. Cells and media were harvested at 40 and 60 h post-
transfection and total IU of helper Ad5/FC31.2 and helper-
dependent Ad5/KCZ were determined (in the whole viral
sample) by end-point dilution assay using fluorescence micro-
scope and X-gal staining, respectively.
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